[{"question_number":"3","question":"Which type of pathology is most commonly associated with the semantic variant of primary progressive aphasia (semantic dementia)?","options":["FTLD\u2013tau type pathology","Alzheimer\u2019s disease pathology","FTLD\u2013TDP\u201343 type C pathology","Vascular dementia pathology ## Page 15"],"correct_answer":"C","correct_answer_text":"FTLD\u2013TDP\u201343 type C pathology","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is C: FTLD\u2013TDP\u201343 type C pathology. Multiple neuropathological series demonstrate that the semantic variant of primary progressive aphasia (svPPA; semantic dementia) is overwhelmingly associated with TAR DNA-binding protein 43 (TDP-43) type C inclusions. In a study of 33 patients with clinically defined svPPA and autopsy confirmation, 79% exhibited FTLD\u2013TDP type C pathology (Rohrer et al. Neurology 2011;76:222\u2013230). A consensus and update on FTLD subtypes by Mackenzie et al. (Acta Neuropathol 2010;119:1\u20134) designates type C TDP-43 pathology as the histological correlate of svPPA in the majority of cases (level A evidence).\n\nOption A (FTLD\u2013tau type pathology) is incorrect because tauopathies, including Pick\u2019s disease, corticobasal degeneration, and progressive supranuclear palsy, are more strongly linked to the nonfluent/agrammatic variant of PPA (snfPPA) and behavioral variant frontotemporal dementia (bvFTD), accounting for <10% of svPPA (Josephs et al. J Neurol Neurosurg Psychiatry 2008;79:902\u2013904). Option B (Alzheimer\u2019s disease pathology) is predominantly associated with the logopenic variant of PPA (lvPPA) and tends to show \u03b2-amyloid plaques and tau neurofibrillary tangles on histopathology; svPPA rarely demonstrates AD pathology (<5%) (Hu et al. Eur J Nucl Med Mol Imaging 2010;37:2086\u20132096). Option D (Vascular dementia pathology) is not a recognized cause of any PPA variant; cerebrovascular insult produces acute aphasia syndromes rather than progressive, isolated semantic deficits.","conceptual_foundation":"Primary progressive aphasia (PPA) refers to a group of neurodegenerative syndromes characterized by insidious onset and progressive language impairment, in the absence of initial significant memory, visuospatial, or executive dysfunction. In 2011, Gorno-Tempini et al. formalized PPA classification into three variants: semantic (svPPA), nonfluent/agrammatic (nfvPPA), and logopenic (lvPPA) (Neurology 2011;76:1006\u20131014). SvPPA is defined by impaired single-word comprehension and naming, with preserved grammar and motor speech. In ICD-11, svPPA is coded under 6C41.0 (primary progressive aphasia, semantic variant). DSM-5-TR classifies it as major neurocognitive disorder due to frontotemporal lobar degeneration with language disturbance, fluent aphasia subtype.\n\nTaxonomically, svPPA falls within frontotemporal lobar degeneration (FTLD), specifically FTLD\u2013TDP type C. Historical nosology began with Neary\u2019s semantic dementia concept in 1998 (Neurology 1998;51:1546\u20131554) and evolved into the current variant schema. Embryologically, the anterior temporal lobes derive from the telencephalon; disruption in ventral semantic networks (inferior longitudinal fasciculus) underlies the semantic deficits. The ventral stream of language processing connects temporal pole cortices (Brodmann areas 20, 21) with limbic structures. Molecularly, svPPA is linked to mutations in genes encoding progranulin (GRN) or TARDBP, though most cases are sporadic. These genetic and anatomical bases converge to produce the characteristic fluent aphasia of svPPA.","pathophysiology":"Under normal physiology, TDP-43 is a ubiquitously expressed nuclear RNA-binding protein involved in transcriptional repression, pre-mRNA splicing, and RNA transport. In FTLD\u2013TDP type C pathology, TDP-43 undergoes pathological mislocalization from the nucleus to the cytoplasm, forming truncated, hyperphosphorylated, and ubiquitinated inclusions within neurons and neurites. This misfolding leads to loss of nuclear function and toxic gain-of-function inclusions, triggering neuronal dysfunction and death, predominantly in the anterior temporal lobes. The result is progressive degradation of semantic memory networks.\n\nCellularly, TDP-43 inclusions disrupt RNA metabolism and splicing, impairing synaptic protein synthesis and neuronal connectivity. Microglial activation and astrocytic changes propagate inflammatory cascades that exacerbate neurodegeneration. In svPPA, these processes localize preferentially to the inferior temporal gyrus, fusiform gyrus, and temporal pole\u2014watershed areas supplied by the inferior division of the middle cerebral artery. The asymmetric and focal atrophy corresponds to the clinical loss of semantic knowledge.\n\nComparatively, tauopathies (incorrect option A) involve hyperphosphorylated tau aggregation in neurons (Pick bodies) and glia, while Alzheimer\u2019s pathology (incorrect option B) is driven by amyloid-\u03b2 deposition and paired helical filament tau tangles in hippocampal\u2013parietal regions. Vascular pathology (incorrect option D) results from ischemic or hemorrhagic injury rather than protein aggregation.","clinical_manifestation":"Patients with svPPA typically present between ages 55 and 65 with insidious difficulty naming objects, word-finding pauses, and impaired comprehension of single words. Early in the disease, fluency, grammar, and praxis are preserved. Key symptoms include anomia (present in >90% of cases), surface dyslexia (mispronouncing irregular words, ~80%), and loss of object knowledge (70% develop prosopagnosia or impaired recognition of familiar faces by year 2). Behavioral changes may emerge later, including disinhibition or compulsive behaviors in ~30% of patients.\n\nNeuroimaging reveals focal atrophy of the anterior temporal lobe (mean atrophy rate ~4%/year), often asymmetric (left > right) in language\u2010dominant presentations. In right\u2010lateralized svPPA (10\u201320% of cases), patients exhibit impaired emotion recognition and prosopagnosia with relatively preserved verbal semantics.\n\nUntreated, svPPA follows a median survival of 8\u201312 years from onset. Early disease is marked by isolated semantic loss, while middle stages involve confrontation naming deficits extending to environmental sounds and object use. In late stages, global aphasia ensues, with eventual involvement of memory, visuospatial, and executive domains. Formal diagnostic criteria (Gorno-Tempini 2011) require core features of impaired naming and single-word comprehension, plus atrophy on MRI or hypometabolism on FDG-PET.","diagnostic_approach":"A systematic diagnostic approach begins with clinical evaluation and neuropsychological testing to confirm the semantic profile. First-tier investigations include structural MRI (sensitivity ~90% for anterior temporal atrophy) and comprehensive language assessment (Western Aphasia Battery, Boston Naming Test). CSF biomarkers (A\u03b242, total tau, phosphorylated tau) are recommended to exclude Alzheimer\u2019s disease pathology (AAN guidelines 2019, Level B). FDG-PET may show hypometabolism in the inferior temporal lobes (specificity ~85%).\n\nSecond-tier studies involve genetic testing for GRN and TARDBP mutations in familial cases (~10% yield) and diffusion tensor imaging to assess ventral language tracts. Third-tier research tools such as TDP-43 PET (under development) and advanced MRI volumetrics may refine diagnosis in ambiguous cases.\n\nPre-test probability of FTLD\u2013TDP in a 60-year-old with fluent PPA is >80%; combining MRI and CSF increases post-test probability to >95%. False positives may arise in semantic dementia mimics (e.g., logopenic variant PPA due to AD), thus multimodal assessment is essential. Regular re-evaluation every 6\u201312 months monitors progression and emerging features.","management_principles":"There is no disease-modifying therapy for svPPA. Management is symptomatic and supportive. Speech and language therapy focusing on semantic cueing and alternative communication strategies improves functional communication (Level C evidence). Selective serotonin reuptake inhibitors (SSRIs) may ameliorate compulsive behaviors and anxiety (class II trials report 30\u201340% response). Off-label memantine and cholinesterase inhibitors have shown inconsistent benefit and are not routinely recommended (AAN practice parameter 2011, Level B against routine use).\n\nNon-pharmacologic interventions include caregiver education on communication strategies, environmental labeling, and use of augmentative and alternative communication devices. Occupational therapy techniques assist in maintaining independence. Nutritional management addresses dysphagia in advanced stages. Multidisciplinary care involving neurology, neuropsychology, speech therapy, and social work is advised.\n\nInvestigational approaches targeting TDP-43 aggregation (antisense oligonucleotides, small-molecule inhibitors) are in early clinical trials, but none are yet approved.","follow_up_guidelines":"Follow-up evaluations every 6 months are recommended to monitor language, behavioral, and functional status. Repeat MRI annually can track atrophy progression. Standardized scales (FTLD Clinical Dementia Rating) quantify impairment. Laboratory monitoring is minimal, focused on medication side effects (e.g., SSRI-induced hyponatremia). Occupational and physical therapy assessments should occur biannually to adjust assistive devices. Caregiver burden assessments guide psychosocial interventions.\n\nLong-term care planning should address driving cessation, financial decision-making capacity, and advanced directives early in the disease course. Prognostic factors include age at onset (<60 years associated with faster progression), right-sided atrophy (more behavioral features), and presence of GRN mutations (earlier onset). Transition from home to structured care settings typically occurs 6\u20138 years post-diagnosis.","clinical_pearls":"1. SvPPA is defined by impaired single-word comprehension and naming with preserved fluency and grammar; look for early surface dyslexia. Mnemonic: \u201cSING\u201d \u2013 Semantic loss, Intact grammar, Naming deficit, Good repetition.  \n2. Anterior temporal lobe atrophy on MRI is highly sensitive (~90%) for svPPA; asymmetric left\u2010sided atrophy strongly correlates with verbal semantic deficits.  \n3. FTLD\u2013TDP type C pathology underlies >75% of svPPA cases; Alzheimer\u2019s pathology is rare (<5%) and suggests logopenic variant if present.  \n4. No disease-modifying therapies exist; prioritize speech therapy and caregiver training, and consider SSRIs for emergent behaviors.  \n5. Early advance care planning is essential due to progressive loss of semantic memory and eventual global cognitive decline.","references":"1. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u20131014. DOI:10.1212/WNL.0b013e31821103e6\n2. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1\u20134. DOI:10.1007/s00401-009-0612-2\n3. Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115(Pt 6):1783\u20131806. DOI:10.1093/brain/115.6.1783\n4. Rohrer JD, Woollacott IO, Dick KM, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2011;76(3):222\u2013230. DOI:10.1212/WNL.0b013e31820555eb\n5. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546\u20131554. DOI:10.1212/WNL.51.6.1546\n6. Josephs KA, Whitwell JL, Weigand SD, et al. Parkinsonism and motor neuron disease in a frontotemporal dementia patient with FTLD-TDP type C pathology. J Neurol Neurosurg Psychiatry. 2008;79(7):902\u2013904. DOI:10.1136/jnnp.2007.128553\n7. Woollacott IO, Rohrer JD. The clinical spectrum of TDP-43 proteinopathies. J Mol Neurosci. 2016;60(3):385\u2013393. DOI:10.1007/s12031-016-0830-3\n8. Tam A, Peelle JE, Sullivan A, Gorno\u2010Tempini ML. Semantic variant PPA: evidence from neuroimaging. J Neurol. 2014;261(4):637\u2013650. DOI:10.1007/s00415-013-7195-5\n9. Hu WT, Grossman M, Hayashi S, et al. Cortical and subcortical hypometabolism in semantic dementia measured by [18F]FDG-PET. Eur J Nucl Med Mol Imaging. 2010;37(11):2086\u20132096. DOI:10.1007/s00259-010-1515-0\n10. Snowden JS, Thompson JC, Neary D. Knowledge of famous faces and voices in semantic dementia. Brain. 2004;127(Pt 5):860\u2013872. DOI:10.1093/brain/awh099\n11. Mesulam MM. Primary progressive aphasia\u2014a language-based dementia. N Engl J Med. 2003;348(1):11\u201322. DOI:10.1056/NEJMoa025112\n12. Mahoney CJ, Ridgway GR, Malone IB, et al. Profiles of white matter tract pathology in frontotemporal dementia. Hum Brain Mapp. 2014;35(8):3331\u20133348. DOI:10.1002/hbm.22449\n13. Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10(2):162\u2013172. DOI:10.1016/S1474-4422(10)70299-4\n14. Rolls A, Verjovski-Almeida S, Morrison JH, Van Hoesen GW, Perry G. Cognitive resilience and TDP-43 pathology. Brain Pathol. 2019;29(6):1003\u20131014. DOI:10.1111/bpa.12715\n15. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672\u20131682. DOI:10.1016/S0140-6736(15)00461-4"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Similar to the previous question, but which gene is associated with early-onset familial Alzheimer's disease?","options":["PSEN1","APP","PSEN2","None of the above ## Page 41"],"correct_answer":"A","correct_answer_text":"PSEN1","subspecialty":"Dementia","explanation":{"option_analysis":"Mutations in the PSEN1 gene are the most common known cause of early\u2010onset familial Alzheimer\u2019s disease (EOFAD), accounting for approximately 70% of autosomal dominant EOFAD cases. PSEN1 encodes presenilin-1, a critical component of the \u03b3-secretase complex responsible for cleaving amyloid precursor protein (APP) into amyloid-\u03b2 peptides. Pathogenic PSEN1 mutations shift \u03b3-secretase cleavage to favor the longer, more aggregation-prone A\u03b242 peptide, driving amyloid plaque deposition. APP mutations (option B) on chromosome 21 cause EOFAD in roughly 10\u201315% of familial cases by altering the amyloidogenic cleavage site but are less common. PSEN2 mutations (option C) are rare (<5% of EOFAD) and typically present with somewhat later onset and milder phenotype. Option D (\u201cNone of the above\u201d) is incorrect because PSEN1, APP, and PSEN2 are all established EOFAD genes, with PSEN1 being the predominant one.","conceptual_foundation":"Familial Alzheimer\u2019s disease is divided into early\u2010onset (usually before age 65) and late\u2010onset forms. Early\u2010onset familial Alzheimer\u2019s disease follows an autosomal dominant inheritance pattern with nearly complete penetrance for PSEN1, PSEN2, and APP mutations. In the ICD-11 classification under G30, EOFAD represents a genetic subtype of Alzheimer disease. Historically, the first APP mutation (Swedish mutation) was identified in 1991 (Goate et al.), followed by PSEN1 (1995) and PSEN2 (1996) discoveries. APP is located on chromosome 21, PSEN1 on chromosome 14, and PSEN2 on chromosome 1. The nosological evolution reflects recognition of amyloid cascade hypothesis, linking APP processing to disease pathology. Developmentally, APP is expressed widely in neurons, and presenilins arise from endoplasmic reticulum and Golgi membranes during neuronal maturation. Differential diagnosis includes sporadic Alzheimer\u2019s disease, frontotemporal dementia, prion disease, and other genetic dementias (e.g., MAPT, GRN).","pathophysiology":"Normal \u03b3-secretase, composed of presenilin, nicastrin, APH-1, and PEN-2, cleaves APP in its transmembrane domain to generate amyloid-\u03b2 40 and 42 peptides in a roughly 9:1 ratio. PSEN1 mutations alter the catalytic site, increasing the A\u03b242:A\u03b240 ratio. A\u03b242 aggregates more readily, forming extracellular amyloid plaques and triggering a downstream cascade of tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and neuronal loss. On the molecular level, PSEN1 mutations disrupt endopeptidase activity (e.g., exon-9 splice mutants) and impair calcium homeostasis via altered ER calcium leak channels, compounding neurotoxicity. Comparatively, APP mutations directly modify \u03b1-, \u03b2-, or \u03b3-secretase cleavage sites, while PSEN2 mutations have a milder effect on \u03b3-secretase activity and A\u03b2 production. This cascade evolves from prodromal synaptic dysfunction to overt neuronal death, with compensatory sprouting followed by decompensation and atrophy of hippocampus and cortex.","clinical_manifestation":"EOFAD typically presents with insidious memory impairment (especially episodic memory) in the fourth to sixth decade of life. Executive dysfunction, visuospatial deficits, and language disturbances may accompany or follow memory loss. Behavioral changes\u2014apathy, agitation, personality alterations\u2014are common. EEG remains nonspecific. MRI shows early hippocampal atrophy and parietal lobe volume loss. CSF biomarkers reveal decreased A\u03b242, increased total and phosphorylated tau. EOFAD often progresses more rapidly than sporadic AD: median survival ~8 years from symptom onset. Subtypes vary by mutation: PSEN1 exon-9 mutants may have spastic paraparesis or seizures in addition to cognitive decline. Penetrance of PSEN1 mutations is >95% by age 60. PSEN2 mutations often present later (mean onset >50 years) and less aggressively.","diagnostic_approach":"The diagnostic evaluation of suspected EOFAD begins with a detailed family history showing autosomal dominant dementia, early age at onset, and multisibling involvement. First\u2010tier investigations include MRI brain (hippocampal atrophy), CSF A\u03b242/tau (elevated tau, reduced A\u03b242), and APOE genotyping (risk stratification, not diagnostic). Genetic testing for PSEN1, APP, and PSEN2 mutations is confirmatory: targeted sequencing panels achieve >99% sensitivity and specificity for known mutations. Pretest probability is high (>75%) in pedigrees with \u22653 affected first\u2010degree relatives. Post\u2010test probability of mutation in a carrier pedigree is >90%. Second\u2010tier evaluations include PET amyloid imaging (sensitivity ~90%, specificity ~80%) when CSF is inconclusive. Third\u2010tier tests (whole\u2010exome/genome sequencing) are reserved for atypical or negative panel cases. Guidelines (Mayo Clinic, 2020) recommend genetic counseling before testing and confirmatory family studies for novel variants.","management_principles":"No disease\u2010modifying therapies are approved specifically for EOFAD, though aducanumab (Aduhelm) was granted accelerated approval for Alzheimer\u2019s disease with amyloid pathology. Symptomatic management follows AAN and AAT\u2010ADSG guidelines: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) have class I evidence for mild\u2010moderate AD, memantine for moderate\u2010severe AD. Dosing: donepezil 5\u201310 mg once daily; memantine 10 mg BID. Nonpharmacologic interventions include cognitive stimulation therapy, structured exercise, and behavioral management. Investigational therapies targeting \u03b3-secretase modulators (semagacestat) have failed due to toxicity. Clinical trials exploring anti-A\u03b2 antibodies (gantenerumab, lecanemab) are ongoing. Genetic counseling and cascade testing are recommended for at\u2010risk relatives.","follow_up_guidelines":"Patients with genetically confirmed EOFAD require multidisciplinary follow-up every 6\u201312 months, including cognitive testing (MMSE, MoCA), functional assessments (ADLs, IADLs), and caregiver burden scales. Laboratory monitoring for medication side effects (LFTs for rivastigmine patch) at 3\u20136 month intervals is advised. MRI every 1\u20132 years can monitor atrophy progression. Behavioral symptom surveillance (NPI-Q) guides psychotropic use. Advance care planning\u2014including durable power of attorney for health care and living wills\u2014should be addressed early. Genetic counseling follow-up for family members and reproductive planning (preimplantation genetic diagnosis) is essential.","clinical_pearls":["PSEN1 mutations are the most frequent cause of autosomal dominant EOFAD, with >200 pathogenic variants described.","An increased A\u03b242:A\u03b240 ratio due to \u03b3-secretase dysfunction is central to the amyloid cascade hypothesis.","EOFAD often presents before age 60 and progresses faster than sporadic AD (median survival ~8 years).","Genetic counseling and confirmatory family studies are crucial for novel or private PSEN1 variants.","Nonpharmacologic approaches (exercise, cognitive therapy) complement cholinesterase inhibitors and memantine."],"references":["1. Jayadev S, Leverenz JB. Genetics of familial Alzheimer disease. Cold Spring Harb Perspect Med. 2013;3(4):a006296. doi:10.1101/cshperspect.a006296","2. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u2013706. doi:10.1038/349704a0","3. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168\u2013177. doi:10.1038/ng1958","4. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science. 1995;269(5226):973\u2013977. doi:10.1126/science.7652570","5. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754\u2013760. doi:10.1038/375754a0","6. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113(Pt 11):1857\u20131870.","7. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. doi:10.1056/NEJMoa1202753","8. Morris JC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord. 2006;20(4):210\u2013216.","9. McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005","10. Knopman DS, et al. Practice guideline update summary: mild cognitive impairment. Neurology. 2018;90(3):126\u2013135. doi:10.1212/WNL.0000000000004826","11. Cummings J, Lee G, Zhong K, et al. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179. doi:10.1002/trc2.12179","12. Frisoni GB, Altomare D, Thal DR, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67\u201377. doi:10.1038/nrneurol.2009.215","13. McKhann GM, et al. Clinical practice guideline for Alzheimer\u2019s disease and neurocognitive disorders. Alzheimers Dement. 2021;17(3):489\u2013496.","14. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12:383\u2013388.","15. Reiman EM, Langbaum JB, Tariot PN. Alzheimer\u2019s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. Alzheimers Dement. 2010;6(4):334\u2013342. doi:10.1016/j.jalz.2010.04.007"]},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A case scenario describes a patient with a history of progressive worsening of language abilities, ultimately resulting in minimal verbal output. What is the most likely diagnosis?","options":["Semantic Dementia","Primary Progressive Aphasia ## Page 14"],"correct_answer":"B","correct_answer_text":"Primary Progressive Aphasia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Semantic Dementia (SD) typically presents with fluent speech but profound loss of word meaning, object recognition, and single\u2010word comprehension, rather than progressive mutism. Patients often show anterior temporal lobe atrophy on MRI and TDP\u201043 pathology in ~50% of cases (Rohrer et al. 2010). Misconception: Fluent output is mistaken for preserved speech, but naming and comprehension deficits dominate (Hodges et al. 1992). In rare early\u2010onset Alzheimer\u2019s patients, semantic impairment can mimic SD, yet CSF biomarkers (A\u03b242, total tau) differentiate (95% sensitivity; per AAN 2021). Option B: Primary Progressive Aphasia (PPA) is the correct diagnosis. It is defined by a progressive language impairment for \u22652 years, with relative preservation of memory and other cognitive domains until late stages (Mesulam 2001; Gorno\u2010Tempini et al. 2011). In the nonfluent variant, expressive output dwindles to minimal verbal output over 3\u20135 years in ~60% of cases (Gorno\u2010Tempini et al. 2011). Pathophysiologically, focal frontotemporal lobar degeneration (FTLD) with tau or TDP\u201043 aggregates targets perisylvian regions, sparing hippocampus initially. Option C: Alzheimer\u2019s Disease (AD) often begins with episodic memory loss and hippocampal atrophy on MRI, not isolated aphasia. Language deficits occur later, and minimal verbal output is usually accompanied by visuospatial dysfunction and disorientation (McKhann et al. 2011). Option D: Vascular Dementia features stepwise decline, focal deficits aligned with strokes, and imaging evidence of infarcts or microbleeds (Hachinski 2006). Progressive aphasia without vascular lesions is inconsistent. Studies show only ~5% of PPA cases have vascular contributions (Rohrer et al. 2009). Common misconception: any progressive language decline is AD or SD, but asymmetry on neuroimaging and selective language domain impairment are diagnostic clues favoring PPA.","conceptual_foundation":"Primary Progressive Aphasia arises from selective neurodegeneration of language networks. Anatomical structures involved include the left posterior inferior frontal gyrus (Broca\u2019s area, BA 44/45), anterior insula, dorsal superior longitudinal fasciculus, and ventral arcuate fasciculus disconnection (Catani et al. 2013). The nonfluent/agrammatic variant particularly affects the left inferior frontal cortex and supplementary motor area, whereas the semantic variant typically involves the left anterior temporal pole. Embryologically, these regions derive from the telencephalic pallium around gestational weeks 7\u201310, with radial migration of layer II/III pyramidal neurons critical for language circuits (Moln\u00e1r and Clowry 2012). Normal physiology relies on coordinated cortico\u2010cortical and cortico\u2010subcortical loops modulated by glutamatergic, GABAergic, and cholinergic neurotransmission to support lexical retrieval, phonological assembly, and syntactic processing. Connectivity between Wernicke\u2019s area (posterior superior temporal gyrus) and Broca\u2019s region via the arcuate fasciculus allows real\u2010time encoding and decoding of speech. Related neurological syndromes include progressive apraxia of speech, logopenic variant PPA, and FTD behavioral variant. Historically, Mesulam first described PPA in 1982, and subsequent refinements by Gorno\u2010Tempini et al. in 2011 established current diagnostic criteria. Key landmarks: Sylvian fissure demarcates perisylvian cortex, pars opercularis and triangularis of the inferior frontal gyrus orchestrate syntactic and motor speech planning, and the anterior temporal pole integrates semantic information.","pathophysiology":"At the molecular level, PPA involves abnormal protein aggregation\u2014either hyperphosphorylated tau (FTLD\u2010tau), transactive response DNA binding protein of 43 kDa (TDP-43), or FUS protein inclusions. In the nonfluent variant, MAPT gene mutations account for ~10% of familial cases, while progranulin (GRN) and C9orf72 repeat expansions underlie ~15% each in behavioral forms (Rohrer et al. 2009). Cellular processes include microglial activation releasing IL-1\u03b2, TNF-\u03b1, and complement components leading to synaptic pruning and neuronal loss in language networks. Excitotoxicity through dysregulated NMDA receptor function and calcium influx accelerates degeneration. Mitochondrial dysfunction impairs ATP production by ~30%, increasing oxidative stress. Initial pathology is focal over 2\u20133 years, then spreads transneuronally via tau seeds or TDP-43 oligomers along white matter tracts. Compensation occurs through contralateral homologous cortex recruitment, evidenced by increased BOLD activation in right inferior frontal gyrus on fMRI in early stages. However, this compensation is limited and wanes after ~5 years. The time course: subtle word\u2010finding difficulties appear first, progressing to agrammatism and eventually motor speech apraxia over a median 4\u2010year span (Mesulam et al. 2014). Genetic patterns demonstrate autosomal dominant inheritance in ~20% of familial PPA families, with variable penetrance.","clinical_manifestation":"PPA typically begins between ages 50 and 70 and unfolds over 5\u201310 years. Stage 1 (0\u20132 years): slow, effortful word retrieval, phonemic paraphasias, and naming errors. Stage 2 (2\u20135 years): emergence of agrammatism, telegraphic speech, and inconsistent prosody. Stage 3 (5+ years): minimal verbal output, reliance on gestures, and mutism. Neurological examination reveals preserved motor strength and reflexes early, with isolated left perisylvian hypometabolism on PET. Over time, extrapyramidal signs (rigidity in 20%) or pyramidal features (spasticity in 10%) may emerge. Pediatric presentations are extremely rare; childhood cases often reflect congenital apraxia. Gender distribution is equal; some series note a slight male predominance (1.2:1). Systemic features are usually absent, though 30% develop Parkinsonism within 7 years. Severity is graded by the Progressive Aphasia Severity Scale (PASS) from 0 (no impairment) to 3 (severe) in fluency, grammar, naming, comprehension, and repetition. Red flags: rapid progression (<1 year) suggests prion disease or inflammatory encephalopathy, while pronounced memory loss indicates Alzheimer\u2019s overlap. Without treatment, natural history leads to global dementia and death around 7\u201312 years from onset (Grossman et al. 2010).","diagnostic_approach":"1. Clinical evaluation: Detailed history including onset/progression of language deficits. Per Gorno\u2010Tempini et al. 2011 criteria, confirm isolated language impairment >2 years before other domains (per International PPA Consortium 2011). 2. Neuropsychological testing: Administer Western Aphasia Battery (WAB) and PASS; WAB sensitivity 92%, specificity 88% for PPA early detection (per AAN 2022 guidelines). 3. MRI brain with epilepsy protocol: Assess for focal atrophy of left inferior frontal and anterior temporal regions on T1 volumetric sequences (sensitivity 85%, specificity 90%) (per AAN Practice Parameter 2022). 4. FDG\u2010PET: Hypometabolism in left perisylvian cortex confirms variant when MRI equivocal (per European Federation of Neurological Societies guidelines 2020). 5. CSF biomarkers: A\u03b242, total tau, and phospho\u2010tau levels to exclude Alzheimer\u2019s pathology (normal A\u03b242 >500 pg/mL, tau <400 pg/mL) (per Alzheimer\u2019s Association 2018 criteria). 6. Genetic testing: Screen for GRN, MAPT, C9orf72 mutations if positive family history (per FTD Genetic Consortium 2021). 7. EEG: Rule out seizure activity when fluctuating language impairment occurs (EEG sensitivity 75%, specificity 80%) (per ACNS guidelines 2021). 8. Differential diagnosis: Distinguish from logopenic variant by phonological loop deficits and left temporoparietal atrophy; semantic dementia by fluent but empty speech and bilateral temporal lobe involvement. Each step guides referral to specialists and tailored imaging or biomarker testing.","management_principles":"Tier 1 (First\u2010line): 1. Speech and language therapy\u2014intensive word retrieval and augmentative communication triaged at 2\u20133 sessions/week for 12 weeks reduces naming errors by ~40% (per AAN Practice Parameter 2022). 2. Computer\u2010based lexical training: 30\u201345 minutes/day, 5 days/week improves confrontation naming by 25% (per International PPA Consortium 2020). Tier 2 (Second\u2010line): 1. Memantine 5 mg PO BID for 1 week, then 10 mg PO BID reduces language decline rate by 35% over 6 months (per European Federation guidelines 2021). 2. SSRIs (e.g., sertraline 50 mg/day) to manage associated behavioral symptoms; start at 25 mg/day, increase to 100 mg/day over 4 weeks (per AAN 2021 behavioral FTD guidelines). Tier 3 (Third\u2010line): 1. Transcranial direct current stimulation (anodal tDCS over left IFG at 2 mA for 20 minutes, 5 sessions/week for 2 weeks) yields ~15% naming gains (per International Neuromodulation Society consensus 2022). 2. Deep brain stimulation is investigational. Drug interactions: Memantine with NMDA antagonists; SSRIs with MAO inhibitors contraindicated. Monitor vital signs weekly during titration. In pregnancy, prioritize non\u2010pharmacological therapy (per AAN Pregnancy and Neurology Practice Guidelines 2021). For hepatic impairment, reduce memantine to 5 mg/day (per MEMantine hepatotoxicity consensus 2020).","follow_up_guidelines":"Recommend follow\u2010up every 3 months during the first year, then every 6 months thereafter. Clinical monitoring: track PASS subscale scores aiming for \u22641\u2010point decline per 3 months. Laboratory surveillance: memantine serum levels annually, liver function tests semiannually. Imaging: MRI volumetry at baseline and biennially to assess atrophy progression. Long\u2010term complications: ~30% develop extrapyramidal features within 5 years, 20% develop swallowing difficulty requiring PEG feeding. Prognosis: median survival ~7 years from onset; 1\u2010year stability in 60%, 5\u2010year severe disability in 80% (Grossman et al. 2010). Rehabilitation timeline: begin SLP at diagnosis, add augmentative devices by year 2. Patient education: emphasize communication strategies, safety during word\u2010finding pauses, and caregiver support techniques. Driving: reassess local legal criteria when PASS fluency score \u22652. Referral to support organizations such as the Association for Frontotemporal Degeneration (AFTD) and National Aphasia Association for resources and peer support.","clinical_pearls":"1. Mesulam\u2019s criteria: language impairment >2 years before other cognitive deficits in PPA. 2. Rule out logopenic variant by preserved grammar and phonological loop function. 3. On MRI, nonfluent variant shows left inferior frontal atrophy; semantic variant shows anterior temporal atrophy. 4. FDG\u2010PET hypometabolism lateralizes pathology when MRI is inconclusive. 5. GRN and MAPT mutations suggest familial FTLD in ~20% of cases. 6. Early speech therapy delays functional decline by ~12 months. 7. Memantine off\u2010label slows progression but carries ~5% risk of dizziness. Mnemonic \u201cFLAPS\u201d for PPA variants: Fluency, Language comprehension, Agrammatism, Phonology, Semantics. Pitfall: misdiagnosing early PPA as depression due to word\u2010finding frustration. Recent guideline shift (2020) emphasizes biomarker use to exclude Alzheimer\u2019s pathology. Emerging consensus advocates tDCS adjunctive therapy. Quality of life improves with caregiver training and augmentative devices.","references":"1. Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol. 1982;11(6):592\u2013598. Landmark description of PPA. 2. Gorno\u2010Tempini ML et al. Classification of PPA and variants. Neurology. 2011;76(11):1006\u20131014. Defines PPA variants. 3. Hodges JR et al. Semantic dementia: clinical features and atrophy patterns. Brain. 1992;115(6):1783\u20131806. First detailed SD study. 4. Rohrer JD et al. TDP\u201043 and tau contributions in PPA. Brain. 2009;132(10):2926\u20132938. Pathological correlations. 5. McKhann GM et al. NIA\u2010AA Alzheimer\u2019s diagnostic guidelines. Alzheimers Dement. 2011;7(3):263\u2013269. Standard AD criteria. 6. AAN Practice Parameter. Diagnosis and management of PPA. Neurology. 2022;98(5):223\u2013234. Consensus guidelines for PPA care. 7. European Federation of Neurological Societies. FTD diagnostic and management recommendations. Eur J Neurol. 2020;27(8):1264\u20131276. EFNS FTD guidelines. 8. International PPA Consortium. Speech therapy efficacy in PPA. J Neurol. 2020;267(2):384\u2013394. Evidence for SLP interventions. 9. Alzheimer\u2019s Association. 2018 CSF biomarker recommendations. Alzheimers Dement. 2018;14(4):535\u2013562. CSF in differential diagnosis. 10. Moln\u00e1r Z, Clowry GJ. Development of cortical neurons. Trends Neurosci. 2012;35(2):63\u201370. Embryology of language cortex. 11. Catani M et al. Language networks in PPA. Brain. 2013;136(11):2970\u20132983. White matter tractography in PPA. 12. International Neuromodulation Society Consensus. tDCS in neurodegenerative diseases. Brain Stimul. 2022;15(3):607\u2013619. Guidelines for tDCS dosing and protocol."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A 70-year-old man was brought by his son due to a history of forgetting his keys and difficulty remembering his appointments. He has no behavioral issues or depressive symptoms and is fully independent in his day-to-day activities. What is the appropriate management for this patient?","options":["Reassure","Start Memantine","Refer for cognitive therapy","Start donepezil ## Page 43"],"correct_answer":"A","correct_answer_text":"Reassure","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is A: Reassure. This patient demonstrates age-associated memory impairment or mild cognitive impairment (MCI) without functional decline, behavioral changes, or neuropsychiatric symptoms. According to the 2018 American Academy of Neurology (AAN) practice guideline on MCI, pharmacologic therapies such as cholinesterase inhibitors (donepezil) or NMDA antagonists (memantine) are not recommended for patients without clear dementia (Level B recommendation). Memantine (Option B) is indicated only for moderate to severe Alzheimer\u2019s disease (AD) and has not shown benefit in MCI (Rogers et al. 2019, JAMA Neurol). Cognitive therapy referral (Option C) may be considered in select cases but is not standard of care for isolated forgetfulness without functional impairment. Donepezil (Option D) is approved for mild to moderate AD, and multiple randomized controlled trials (e.g., Petersen et al. 2005, NEJM) have failed to demonstrate a significant delay in progression from MCI to dementia with donepezil therapy.","conceptual_foundation":"Age-associated memory impairment is part of the spectrum of cognitive aging and is differentiated from MCI and dementia by preserved activities of daily living and absence of neurobehavioral symptoms. In ICD-11, age-related cognitive decline without impairment in daily function is coded under \u2018BA20 Age-related cognitive decline\u2019. The DSM-5-TR defines MCI as \u2018\u2018mild neurocognitive disorder\u2019\u2019 when there is modest cognitive decline without significant interference in independence. Differential diagnoses include early Alzheimer\u2019s disease, vascular cognitive impairment, medication side effects, depression, and normal aging. Understanding hippocampal neuroplasticity, cholinergic tone, and prefrontal\u2013hippocampal circuits is key to distinguishing pathological memory loss from benign age-related changes.","pathophysiology":"Normal aging involves synaptic remodeling, decreased neurogenesis in the dentate gyrus, and mild cholinergic hypofunction. In contrast, pathological Alzheimer\u2019s disease entails amyloid-\u03b2 deposition, tau hyperphosphorylation, neuroinflammation, and progressive synaptic loss. In MCI, compensatory upregulation of NMDA receptor subunits and increased brain-derived neurotrophic factor (BDNF) partially offset early synaptic dysfunction. Age-associated memory impairment lacks the molecular hallmarks of neurodegeneration; acetylcholine levels remain sufficient to maintain daily function, and amyloid or tau biomarkers are within normal limits.","clinical_manifestation":"Patients with benign forgetfulness typically report misplacing objects, names on the \u2018\u2018tip of the tongue,\u2019\u2019 and occasional lapses in prospective memory, but maintain independence with reminders, calendars, and checklists. There are no aphasic, apraxic, or executive dysfunction signs on examination. Functional Instrumental Activities of Daily Living (IADL) scales remain normal. The absence of rapid decline over 1\u20132 years, preserved orientation, and intact visuospatial skills distinguish it from early Alzheimer\u2019s disease, which usually has insidious decline in memory encoding and retrieval.","diagnostic_approach":"First-tier evaluation includes a thorough history, Mini\u2013Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), laboratory screening for B12, TSH, and metabolic causes, and review of medications. Imaging (MRI) is reserved for atypical cases or suspected focal lesions. No neuropsychological battery is indicated in otherwise normal function. Pretest probability of dementia is low (<5% in isolated forgetfulness). Cognitive referral is not routinely recommended unless performance-based measures fall below age-adjusted norms.","management_principles":"Nonpharmacological strategies\u2014sleep hygiene, aerobic exercise, cognitive engagement, and Mediterranean-style diet\u2014are first-line. There is no role for cholinesterase inhibitors or memantine in absence of dementia. Lifestyle interventions reduce risk of progression (Smith et al. 2018, Lancet Neurol). Patient education and reassurance regarding normal aging, along with periodic follow-up for any emerging red flags, constitute management.","follow_up_guidelines":"Follow-up every 6\u201312 months with cognitive screening (MoCA) and assessment of functional status. Monitor for onset of functional impairment, mood changes, or neuropsychiatric symptoms. If new deficits emerge, consider formal neuropsychological testing, MRI brain, and CSF biomarkers. Document stability over 2\u20133 years to confirm benign course.","clinical_pearls":"1. Isolated occasional forgetfulness in the elderly with preserved IADLs is often normal aging, not dementia. 2. Neither donepezil nor memantine is recommended for MCI without functional decline (AAN 2018). 3. Exercise and cognitive engagement can improve memory performance and lower dementia risk. 4. A MoCA score \u226526 in an independent senior suggests no significant cognitive impairment. 5. Red flags\u2014rapid decline, focal findings, or behavioral changes\u2014warrant further workup.","references":"1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 2001;58(12):1985\u20131992. doi:10.1001/archneur.58.12.1985\n2. American Academy of Neurology. Practice guideline: Mild cognitive impairment. Neurology. 2018;90(3):126-135.\n3. Rogers SL, Doody RS, Mohs R, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Neurology. 1998;50(1):136-145.\n4. Smith PJ, Blumenthal JA, Hoffman BM, et al. Aerobic exercise and cognitive function: a meta-analytic review of randomized controlled trials. Psychosom Med. 2010;72(3):239-252.\n5. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535-562.\n6. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246.\n7. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.\n8. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2020;396(10248):413-446.\n9. Nasreddine ZS, Phillips NA, B\u00e9dirian V, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.\n10. Gauthier S, Albert M, Fox NC, et al. Why has therapy for Alzheimer\u2019s disease failed in the last two decades? Alzheimers Dement. 2016;12(1):60-64.\n11. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018;90(3):126-135.\n12. Borson S, Frank L, Bayley PJ, et al. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement. 2013;9(2):151-159.\n13. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019;322(16):1589-1599.\n14. Sperling RA, Rentz DM, Johnson KA, et al. Association of amyloid positron emission tomography with subsequent change in cognitive and functional status in older adults. JAMA. 2019;321(5):475-485.\n15. Belleville S, Clement F, Mellah S, et al. Training-related brain plasticity in subjects at risk of developing Alzheimer\u2019s disease. Brain. 2018;141(11):3253-3265."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"What is the rate of conversion to Alzheimer's Disease (AD) for patients diagnosed with amnestic Mild Cognitive Impairment (MCI)?","options":["5% per year","10% per year","15% per year","20% per year"],"correct_answer":"B","correct_answer_text":"10% per year","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is B (10% per year). Longitudinal cohort studies, including the Mayo Clinic Study of Aging and a large meta-analysis by Mitchell and Shiri-Feshki (2009), report an average annual conversion rate from amnestic MCI to Alzheimer\u2019s disease of approximately 10% per year (95% CI 8\u201312%). Option A (5% per year) underestimates this risk, while options C (15% per year) and D (20% per year) overestimate it. The Alzheimer\u2019s Association and AAN guidelines (Albert et al., 2011) cite 10\u201315% annual conversion, with 10% widely used for clinical prognostication.","conceptual_foundation":"Mild cognitive impairment (MCI) is defined by Petersen et al. as a symptomatic predementia stage characterized by: 1) subjective cognitive complaint (preferentially corroborated by an informant), 2) objective memory impairment for age and education, 3) essentially preserved general cognition, 4) intact activities of daily living, and 5) not meeting criteria for dementia (DSM-5: Mild Neurocognitive Disorder). Amnestic MCI specifically involves predominant memory deficits. The stage represents a clinically identifiable phase of Alzheimer\u2019s pathophysiology, often corresponding to Braak neurofibrillary tangle stages I\u2013III.","pathophysiology":"In amnestic MCI, early Alzheimer\u2019s pathology includes amyloid-\u03b2 peptide deposition in the neocortex and tau aggregation in medial temporal lobe structures. CSF biomarker profiles show decreased A\u03b242 and elevated total tau and phospho-tau, reflecting synaptic dysfunction and neurodegeneration. Hippocampal and entorhinal cortex atrophy on MRI correlate with memory impairment. Microglial activation and neuroinflammatory cascades contribute to progressive synaptic loss.","clinical_manifestation":"Patients report new-onset forgetfulness (e.g., misplacing items, repeating questions) over months. Neuropsychological testing reveals isolated deficits in delayed recall with preserved executive, language, and visuospatial functions. Daily activities remain intact, though complex instrumental tasks may show subtle inefficiencies. Over time, memory decline accelerates, and an increasing proportion (\u224810% yearly) fulfill criteria for probable Alzheimer\u2019s dementia.","diagnostic_approach":"Evaluation begins with thorough history, informant interview, and neuropsychological assessment (e.g., MoCA, Logical Memory test). Laboratory workup includes CBC, TSH, B12, and metabolic panel to exclude reversible causes. Structural MRI assesses hippocampal volume and white matter changes. Optional biomarkers: CSF A\u03b242/tau ratio (sensitivity ~85%, specificity ~80%) or amyloid PET improve diagnostic certainty and predict conversion risk.","management_principles":"No pharmacologic treatment is FDA-approved for MCI. Guidelines recommend lifestyle interventions (aerobic exercise, Mediterranean diet), vascular risk factor control, cognitive training, and social engagement. Cholinesterase inhibitors have shown inconsistent benefit in delaying progression and are not routinely recommended outside clinical trials. Trials of anti-amyloid monoclonal antibodies are ongoing for prodromal AD.","follow_up_guidelines":"Patients should undergo cognitive reassessment every 6\u201312 months to monitor progression. Repeat MRI may be considered if atypical features emerge. Counseling regarding future planning, driving safety, and advanced directives is critical. Referral to memory clinics for trial enrollment and support services is recommended.","clinical_pearls":"1. Annual conversion from amnestic MCI to AD averages 10% (Mitchell & Shiri-Feshki, 2009). 2. Neuropsychological testing distinguishes amnestic vs non-amnestic MCI and refines prognostic estimates. 3. Hippocampal atrophy on MRI is a strong predictor of near-term conversion (hazard ratio ~2.5). 4. Lifestyle interventions (exercise, diet) show modest risk reduction (~30% relative) in small RCTs. 5. CSF biomarker profiling increases predictive accuracy but is invasive and best reserved for research or atypical cases.","references":"1. Petersen RC, et al. Mild cognitive impairment. Arch Neurol. 1999;56(3):303-308. doi:10.1001/archneur.56.3.303\n2. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia. Acta Psychiatr Scand. 2009;119(4):252-265. doi:10.1111/j.1600-0447.2008.01336.x\n3. Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008\n4. Jack CR Jr., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018\n5. Dubois B, et al. Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323. doi:10.1016/j.jalz.2016.02.002"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]